跳到正文
原文
Medical Xpress·· 2026-10-07精选AI 评分70

Fred Hutch 研究发现 tRNA1Arg(UCU) 调控前列腺癌雄激素受体依赖性与耐药

Key driver of aggressive prostate cancer identified, suggesting new way to reverse drug resistance

AI 导读

Fred Hutch 癌症中心团队在 Nature 发表研究,发现 tRNA1Arg(UCU) 水平在前列腺癌细胞中与雄激素受体依赖性和治疗敏感性相关。在细胞系、小鼠模型和患者肿瘤样本中,该 tRNA 水平高的肿瘤更依赖雄激素受体、对靶向雄激素受体的治疗更敏感;在实验模型中给予该 tRNA,可使耐药肿瘤恢复对这类治疗的敏感性。

推荐理由

研究在细胞系、小鼠模型与患者肿瘤样本中追踪同一 tRNA 的水平变化,为理解前列腺癌治疗抵抗提供分子线索。

正文
Key driver of aggressive prostate cancer identified, suggesting new way to reverse drug resistance
Microscope image of human prostate cancer with a high amount of a distinct tRNA, as shown in dark purple/pink staining. High amounts of a specific tRNA (called tRNA1Arg(UCU)) were associated with the prostate tumor being dependent on the androgen receptor for growth and with sensitivity to therapies that target the androgen receptor. Credit: Hsieh Lab, Fred Hutch Cancer Center

Researchers at Fred Hutch Cancer Center have identified a previously overlooked molecular regulator that helps determine whether prostate tumors remain sensitive to treatment or evolve into a more aggressive, drug-resistant form of the disease.

The findings, published in Nature, reveal for the first time that a single transfer RNA, or tRNA, can control the identity of prostate cancer cells and influence their response to therapy.

"The discovery opens an entirely new realm of cancer biology that was previously unrecognized," said co-corresponding author Andrew Hsieh, a professor and associate director of Fred Hutch's Human Biology Division. "Historically, tRNAs have been thought to play a bystander role in cell maintenance and disease, but our study shows that tRNAs can actively shape the identity of cancer cells."

Tracing the shift to treatment resistance

Prostate cancer, a leading cause of cancer in men, can shift cellular characteristics over time. Initially, prostate cancer depends on the activity of the androgen receptor, a protein that fuels tumor growth and is the primary target of standard therapies. But then many tumors shift to an androgen receptor–independent state. Once independent of the androgen receptor, prostate cancer tumors become more aggressive and less responsive to therapy.

Yeon Soo Kim, first author of the Nature paper and a Fred Hutch postdoctoral researcher in Hsieh's lab, sought to understand the molecular players underlying how prostate cancer changes its identity and becomes resistant to treatment.

"We already knew that genomic mutations or transcription factor–dependent gene expression are altered during cancer progression and can lead to the development of treatment resistance," Kim explained. "But we wanted to know more about how mRNA translation—also known as protein synthesis—is involved when the disease becomes more aggressive."

Kim examined one of the steps in mRNA translation: when tRNA takes biological information from mRNA to deliver amino acids that combine to build proteins.

Kim used prostate cancer cell lines, mouse models and tumor samples from patients to examine the role of tRNA in the transition to the aggressive form of prostate cancer.

Key driver of aggressive prostate cancer identified, suggesting new way to reverse drug resistance
Microscope image of human prostate cancer with a low amount of a distinct tRNA, as shown in few areas of pink staining. Low amounts of a specific tRNA (called tRNA1Arg(UCU)) in prostate tumors were associated with the tumor being less androgen receptor dependent and therefore less likely to respond to androgen receptor targeting therapies. Credit: Dr. Yeon Soo Kim, Hsieh Lab, Fred Hutch Cancer Center.

A single tRNA restores treatment sensitivity

Across all model systems, Kim and her co-authors observed a consistent pattern: Levels of a specific tRNA called tRNA1Arg(UCU) were high in androgen receptor–dependent prostate cancer cells but diminished in less androgen receptor–dependent, treatment-resistant tumors.

Then, Kim did additional experiments and found that treatment-resistant tumors, when given the specific tRNA, could go back to being sensitive to treatments targeting the androgen receptor.

"We found that we can shift the cell state between an androgen receptor–dependent state and an androgen receptor–independent state with a single tRNA," Kim said. "This is important because changes in cell identity are a major reason prostate cancers become resistant to treatment. We found that this tRNA can influence whether cells remain in a drug-sensitive state or transition to one that is more aggressive."

Exploring biomarkers and other cancer types

The findings could be applied to other diseases, too.

"In this study, we used prostate cancer as an archetype to study tRNA-dependent state changes, but we think it's just the beginning," said Kim, who is planning to pursue such studies when she establishes her own lab. "We can apply this approach to any type of disease model or other types of cancers that undergo identity switches after treatment, such as lung and breast cancers."

Kim and Hsieh are also looking into how tRNA could be used as a biomarker or therapeutic target for aggressive prostate cancer, which could help guide more precise treatments or new treatments for patients.

Hsieh holds the Larry and Virginia Gordon Endowed Chair in Prostate and Bladder Cancer Research at Fred Hutch. He is also a professor in the Division of Hematology and Oncology at the University of Washington School of Medicine. Co-corresponding author Tao Pan is at the University of Chicago.

Publication details

Andrew Hsieh, tRNA dosage regulates lineage dependency and resistance in prostate cancer, Nature (2026). DOI: 10.1038/s41586-026-11153-8. www.nature.com/articles/s41586-026-11153-8

Journal information: Nature

Who's behind this story?

Sadie Harley

Sadie Harley

BSc Life Sciences & Ecology. Microbiology lab background with pharmaceutical news experience in oil, gas, and renewable industries. Full profile →

Robert Egan

Robert Egan

Bachelor's in mathematical biology, Master's in creative writing. Well-traveled with unique perspectives on science and language. Full profile →

Citation: Key driver of aggressive prostate cancer identified, suggesting new way to reverse drug resistance (2026, October 7) retrieved 7 October 2026 from https://medicalxpress.com/news/2026-10-key-driver-aggressive-prostate-cancer.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

来源:Medical Xpress · medicalxpress.com